Orbit Discovery - Delivering Peptide Discovery Solutions

Peptide Discovery

Delivering Peptide Discovery Solutions

What We Do

Orbit Discovery provides peptide discovery services for therapeutic applications, including radionuclide targeting, nucleic acid targeting, targeted protein degradation, soluble protein targeting and GPCR agonism and antagonism.

We combine our bead-based display system and microfluidics to perform high-throughput screening across very large chemical spaces, including both linear and macrocyclic peptide development.

Our services are customizable for both affinity screening (targeting binders) and direct functional screening (especially for agonism and antagonism) using proprietary reporter cell lines.

Our mission is to help partners identify peptide therapeutic hits through advanced high-throughput affinity and functional screening techniques.

The Orbit Display Bead:
Peptide and Encoding DNA: Linked

Applications

Radiopharmaceutical Targeting

Orbit Discovery finds peptide conjugates for precise radionuclide delivery. Using bead-based technology and flow cytometry, we identify high-affinity peptides for tumor-specific targets. Our diverse peptide libraries enhance target specificity while minimising off-target effects.

Functional Screening

Orbit's screening platform leverages microfluidics to screen directly for function against reporter cells, making it ideal for identifying GPCR agonists and antagonists. Our approach enables screens that are cover larger chemical space than traditional plate-based techniques.

Nucleic Acid Delivery

Orbit Discovery enhances peptide conjugate discovery for targeted RNA delivery. Using our bead-based technology, we identify peptides with strong affinities for disease-specific targets. As part of the validation process, we can screen large numbers of peptides for internalisation, ensuring accurate delivery for effective targeted therapies.

Soluble Protein Targeting

Orbit excels in discovering peptides against soluble proteins such as actuators for Target Protein Degradation. Our flexible platform supports multiple selections, counter-target screening, and precise tuning to binding sites, making it ideal for coupling high-affinity binders to ubiquitin ligases for PROTACs.

Our Platform

Learn More

Latest Updates

Orbit Discovery - Spring 2025 Newsletter Available

March 24, 2025

Orbit Discovery recently published is Spring 2025 Newsletter

Orbit Discovery to Attend Bio-Europe Spring 2025

March 10, 2025

Orbit CEO, Neil Butt, and Simon Bushell (Business Development) will be attending Bio Europe Spring in Milan, Italy from March 17th-19th.

Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

December 3, 2024

Oxford, UK, and Springfield, NJ, USA, 3rd December 2024: – Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced an extension to their research collaboration to find novel targeting peptides for radiopharmaceutical delivery. This collaboration expands upon a previous agreement signed between Orbit and Evergreen the companies in April 2023 whereby technology synergies have enabled the identification of high-affinity peptide ligands optimized for precision therapeutic applications.